- Home
- VIRC vs PLX Comparison
VIRC vs PLX Comparison
Compare VIRC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIRC
- PLX
- Stock Information
- Founded
- VIRC 1950
- PLX 1993
- Country
- VIRC United States
- PLX Israel
- Employees
- VIRC N/A
- PLX N/A
- Industry
- VIRC Industrial Specialties
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VIRC Consumer Discretionary
- PLX Health Care
- Exchange
- VIRC Nasdaq
- PLX Nasdaq
- Market Cap
- VIRC 176.7M
- PLX 160.2M
- IPO Year
- VIRC N/A
- PLX 1998
- Fundamental
- Price
- VIRC $10.05
- PLX $2.22
- Analyst Decision
- VIRC Buy
- PLX
- Analyst Count
- VIRC 1
- PLX 0
- Target Price
- VIRC $19.00
- PLX N/A
- AVG Volume (30 Days)
- VIRC 156.2K
- PLX 553.9K
- Earning Date
- VIRC 12-09-2024
- PLX 03-13-2025
- Dividend Yield
- VIRC 0.90%
- PLX N/A
- EPS Growth
- VIRC N/A
- PLX N/A
- EPS
- VIRC 1.53
- PLX N/A
- Revenue
- VIRC $280,375,000.00
- PLX $45,667,000.00
- Revenue This Year
- VIRC $6.43
- PLX N/A
- Revenue Next Year
- VIRC $2.38
- PLX $90.00
- P/E Ratio
- VIRC $6.57
- PLX N/A
- Revenue Growth
- VIRC 5.68
- PLX N/A
- 52 Week Low
- VIRC $8.75
- PLX $0.82
- 52 Week High
- VIRC $18.50
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- VIRC 37.03
- PLX 74.10
- Support Level
- VIRC $9.08
- PLX $2.11
- Resistance Level
- VIRC $10.45
- PLX $2.36
- Average True Range (ATR)
- VIRC 0.37
- PLX 0.12
- MACD
- VIRC 0.19
- PLX 0.00
- Stochastic Oscillator
- VIRC 55.43
- PLX 77.42
About VIRC Virco Manufacturing Corporation
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, and activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.